Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.50 |
| ▸ | SLC6A12 | P48065 | 3/20 | 0.41 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL457824 | 1.00 | EPHX1 (0.51) | EPHX1TRPM8TRPA1SLC6A12SLC6A11 | |
| Formaldehyde SCHEMBL31298519 | 0.96 | EPHX1 (0.49) | EPHX1TRPM8TRPA1SLC6A12SLC6A11 | |
| Acetic Acid SCHEMBL30541669 | 0.96 | EPHX1 (0.49) | EPHX1TRPM8TRPA1SLC6A12SLC6A11 | |
| SCHEMBL3855216 | 0.86 | EPHX1 (0.50) | EPHX1TRPM8TRPA1TRPV1 | |
| SCHEMBL11291061 | 0.86 | EPHX1 (0.49) | EPHX1TRPM8TRPA1KCNA5TRPV1 | |
| SCHEMBL29992331 | 0.85 | EPHX1 (0.49) | EPHX1MEN1KMT2ACYP19A1 | |
| SCHEMBL29450749 | 0.85 | EPHX1 (0.49) | EPHX1MEN1KMT2ACYP19A1 | |
| SCHEMBL29590959 | 0.85 | EPHX1 (0.49) | EPHX1MEN1KMT2ACYP19A1 | |
| SCHEMBL9951688 | 0.85 | EPHX1 (0.51) | EPHX1TRPM8TRPA1TRPV1CYP19A1 | |
| SCHEMBL9951381 | 0.85 | EPHX1 (0.51) | EPHX1TRPM8TRPA1TRPV1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025045354-A1 | A FRAGRANCE TABLET | SYMRISE AG (DE) | 2025-03-06 | — | — | WO | claimed |
| WO-2025045353-A1 | A FRAGRANCE POD | SYMRISE AG (DE) | 2025-03-06 | — | — | WO | claimed |
| WO-2026046686-A1 | EVAPORATING MICROEMULSIONS | SYMRISE AG (DE) | 2026-03-05 | — | — | WO | disclosed |
| WO-2026046506-A1 | EVAPORATING MICROEMULSIONS | SYMRISE AG (DE) | 2026-03-05 | — | — | WO | disclosed |
| EP-4623057-A1 | ENCAPSULATED FRAGRANCE COMPOSITIONS FOR PROVIDING, MODULATING OR INTENSIFYING A SCENT | Symrise AG (DE) | 2025-10-01 | — | — | EP | disclosed |
| WO-2025119505-A1 | ENCAPSULATED FRAGRANCE COMPOSITIONS FOR PROVIDING, MODULATING OR INTENSIFYING A SCENT | SYMRISE AG (DE) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025051340-A1 | TRPM8 MODULATORS AND RELATED METHOD FOR MODULATING TRPM8 RECEPTORS | SYMRISE AG (DE) | 2025-03-13 | — | — | WO | disclosed |
| CN-114502138-A | Improvements in or relating to organic compounds | 奇华顿股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20120165559-A1 | Compounds Having a Physiological Effect | V. MANE FILS (FR) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165559-A1 | Compounds Having a Physiological Effect | NPPA, CYP11B2, SHBG | EPHX1 871/4885TRPM8 412/4885TRPA1 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.